A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

October 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

December 31, 2011

Conditions

Wheezing

Interventions

BIOLOGICAL

Motavizumab

15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections

OTHER

Placebo

15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections